You are here: Industry Insights > inhibitors

News List

Octapharma puts a spotlight on the challenges of managing inhibitors in haemophilia A at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) prnasia
January 20, 2022
The virtual symposium held on Wednesday, February 2, 2022, at 18:00 CET, will tell the story of the Rodriguez family and their two sons with haemophilia A as they navigate the challenges of inhibitor management.
Antihistamines can influence immunotherapy response by enhancing T cell activation FirstWordPharma
November 29, 2021
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors.
Moleculin, UTMB Evaluate Inhibitors for Antiviral Properties contractpharma
March 18, 2020
Moleculin will supply the lead drug candidate, WP1122, and related inhibitors, as well as technical support.
SGLT2 Inhibitors Linked to Lower Risk for Heart Failure drugs
September 23, 2019
Use of sodium glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes is associated with a reduced risk for heart failure ...
“Upstar” against Breast Cancer—CDK 4/6 Inhibitors: Which has the Biggest Potential among the Three? PharmaSources/Dopine
August 20, 2019
Targeted therapies have played an increasingly important role in tumor treatment in recent years.
Higher Cost of New Cholesterol Drugs Putting Patients at Risk: Study drugs
July 24, 2019
Heart attacks, strokes and other heart problems are more likely in high-risk patients denied access to cutting-edge cholesterol-busting drugs called PCSK9 inhibitors...
Newer Drug Extends Lives of Young Breast Cancer Patients drugs
June 03, 2019
Adding a newer drug to standard hormone therapy lengthens the lives of younger women with advanced breast cancer, a new trial has found.
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors worldpharmanews
March 06, 2019
Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology.
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors worldpharmanews
March 06, 2019
Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology.
Study may explain why once-promising cancer drugs failed worldpharmanews
January 29, 2019
Nearly two decades after a class of once-promising cancer drugs called MMP inhibitors mysteriously failed in clinical trials

Previous page 1 2 3 Next page